Table 3.
Adjudicated serious CCV AEs during the study (safety set)
| Adjudicated event | Glycopyrrolate N=222, n (%) | Placebo N=216, n (%) |
|---|---|---|
| Patients with at least one serious CCV AE | 5 (2.3) | 6 (2.8) |
| MACE | 2 (0.9) | 5 (2.3) |
| Nonfatal myocardial infarction | 2 (0.9) | 1 (0.5) |
| Coronary revascularization (CABG or PCI) | 0 | 3 (1.4) |
| Heart failure requiring hospitalization | 0 | 1 (0.5) |
| Nonfatal stroke | 0 | 1 (0.5) |
| Non-MACE serious CCV AE | 3 (1.4) | 4 (1.9) |
Abbreviations: AE, adverse event; CABG, coronary artery bypass grafting; CCV, cerebro- and cardiovascular; MACE, major adverse cardiovascular events; PCI, percutaneous coronary intervention.